SK140699A3 - Amidine derivatives, preparation method thereof, compositions containing them and their use for the treatment - Google Patents

Amidine derivatives, preparation method thereof, compositions containing them and their use for the treatment Download PDF

Info

Publication number: SK140699A3
Authority: SK; Slovakia
Prior art keywords: formula; compound; pharmaceutically acceptable; condition; disease
Prior art date: 1997-05-05

Application number

SK1406-99A

Other languages

English (en)

Slovak (sk)

Inventor

James Macdonald

James Matz

William Shakespeare

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-05

Filing date

1998-04-28

Publication date

2000-06-12

1998-04-28 Application filed by Astra Ab filed Critical Astra Ab

2000-06-12 Publication of SK140699A3 publication Critical patent/SK140699A3/sk

Links

238000002360 preparation method Methods 0.000 title claims abstract description 10
238000011282 treatment Methods 0.000 title claims description 23
239000000203 mixture Substances 0.000 title abstract description 25
150000001409 amidines Chemical class 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 112
150000003839 salts Chemical class 0.000 claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 38
230000003287 optical effect Effects 0.000 claims abstract description 26
230000008569 process Effects 0.000 claims abstract description 11
230000001537 neural effect Effects 0.000 claims abstract description 9
102000001708 Protein Isoforms Human genes 0.000 claims abstract description 7
108010029485 Protein Isoforms Proteins 0.000 claims abstract description 7
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 6
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 3
102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 18
108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
208000002193 Pain Diseases 0.000 claims description 14
230000036407 pain Effects 0.000 claims description 14
238000011321 prophylaxis Methods 0.000 claims description 11
208000018737 Parkinson disease Diseases 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 10
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 10
201000000980 schizophrenia Diseases 0.000 claims description 10
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
206010021143 Hypoxia Diseases 0.000 claims description 9
230000007954 hypoxia Effects 0.000 claims description 9
208000006011 Stroke Diseases 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
208000028867 ischemia Diseases 0.000 claims description 8
230000005764 inhibitory process Effects 0.000 claims description 7
208000023105 Huntington disease Diseases 0.000 claims description 6
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
229960005181 morphine Drugs 0.000 claims description 5
229940127240 opiate Drugs 0.000 claims description 5
206010013654 Drug abuse Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
235000019253 formic acid Nutrition 0.000 claims description 3
CSACSOOYFUXTIP-UHFFFAOYSA-N n'-(2-methyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C1=C2CN(C)CCC2=CC=C1NC(=N)C1=CC=CS1 CSACSOOYFUXTIP-UHFFFAOYSA-N 0.000 claims description 3
LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 2
VZKZUPIDSUVHLB-UHFFFAOYSA-N n'-(2-butyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C1=C2CN(CCCC)CCC2=CC=C1NC(=N)C1=CC=CS1 VZKZUPIDSUVHLB-UHFFFAOYSA-N 0.000 claims description 2
HWZSHHNOIXRTJD-UHFFFAOYSA-N n'-(2-ethyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C1=C2CN(CC)CCC2=CC=C1NC(=N)C1=CC=CS1 HWZSHHNOIXRTJD-UHFFFAOYSA-N 0.000 claims description 2
LGOGDAYURLJNDA-UHFFFAOYSA-N n'-(2-propan-2-yl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C1=C2CN(C(C)C)CCC2=CC=C1N=C(N)C1=CC=CS1 LGOGDAYURLJNDA-UHFFFAOYSA-N 0.000 claims description 2
SKBCFDVCRLYJNH-UHFFFAOYSA-N n'-(2-propyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C1=C2CN(CCC)CCC2=CC=C1NC(=N)C1=CC=CS1 SKBCFDVCRLYJNH-UHFFFAOYSA-N 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
239000000014 opioid analgesic Substances 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
230000009286 beneficial effect Effects 0.000 claims 2
239000003612 morphinomimetic agent Substances 0.000 claims 2
150000004908 diazepines Chemical class 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 abstract description 3
125000000217 alkyl group Chemical group 0.000 abstract description 2
229940124639 Selective inhibitor Drugs 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000002904 solvent Substances 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
229930064664 L-arginine Natural products 0.000 description 6
235000014852 L-arginine Nutrition 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
239000004475 Arginine Substances 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 5
239000012131 assay buffer Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
229960002173 citrulline Drugs 0.000 description 5
238000001914 filtration Methods 0.000 description 5
QKOYZKQATHHROV-UHFFFAOYSA-N 2-methyl-3,4-dihydro-1h-isoquinolin-7-amine;hydrochloride Chemical compound Cl.C1=C(N)C=C2CN(C)CCC2=C1 QKOYZKQATHHROV-UHFFFAOYSA-N 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
101710111444 Nitric oxide synthase, brain Proteins 0.000 description 4
101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
238000006396 nitration reaction Methods 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
YPRWYZSUBZXORL-UHFFFAOYSA-N 7-nitro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=CC([N+](=O)[O-])=CC=C21 YPRWYZSUBZXORL-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
-1 aryl alcohols Chemical class 0.000 description 3
239000002585 base Substances 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
125000004989 dicarbonyl group Chemical group 0.000 description 3
FVUJVFWRFKNWLS-UHFFFAOYSA-N ethyl thiophene-2-carboximidothioate;hydrochloride Chemical compound Cl.CCSC(=N)C1=CC=CS1 FVUJVFWRFKNWLS-UHFFFAOYSA-N 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
APTCPYGFVKKBME-UHFFFAOYSA-N n'-(2-methyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=C2CN(C)CCC2=CC=C1NC(=N)C1=CC=CS1 APTCPYGFVKKBME-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
238000003345 scintillation counting Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000004001 thioalkyl group Chemical group 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
WYGYMIKICPQWCH-UHFFFAOYSA-N 2-ethyl-7-nitro-3,4-dihydro-1h-isoquinoline Chemical compound C1=C([N+]([O-])=O)C=C2CN(CC)CCC2=C1 WYGYMIKICPQWCH-UHFFFAOYSA-N 0.000 description 2
XCQDUCOKROUHJP-UHFFFAOYSA-N 2-methyl-7-nitro-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1=C([N+]([O-])=O)C=C2CN(C)CCC2=C1 XCQDUCOKROUHJP-UHFFFAOYSA-N 0.000 description 2
UDPFIKUSCVFPQT-UHFFFAOYSA-N 2-propyl-3,4-dihydro-1h-isoquinolin-7-amine;hydrochloride Chemical compound Cl.C1=C(N)C=C2CN(CCC)CCC2=C1 UDPFIKUSCVFPQT-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
PNNFEOFKVITLEM-UHFFFAOYSA-N 7-nitro-2-propyl-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1=C([N+]([O-])=O)C=C2CN(CCC)CCC2=C1 PNNFEOFKVITLEM-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000018152 Cerebral disease Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
GMPBHUGVOJDXBO-UHFFFAOYSA-N methyl thiophene-3-carboximidothioate hydroiodide Chemical compound I.CSC(=N)c1ccsc1 GMPBHUGVOJDXBO-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
YAUBARALXQKENX-UHFFFAOYSA-N n'-(1,2,3,4-tetrahydroisoquinolin-7-yl)thiophene-2-carboximidamide Chemical compound C=1C=C2CCNCC2=CC=1NC(=N)C1=CC=CS1 YAUBARALXQKENX-UHFFFAOYSA-N 0.000 description 2
PIHWSGQFQREIRT-UHFFFAOYSA-N n'-(2-propyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=C2CN(CCC)CCC2=CC=C1NC(=N)C1=CC=CS1 PIHWSGQFQREIRT-UHFFFAOYSA-N 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000004323 potassium nitrate Substances 0.000 description 2
235000010333 potassium nitrate Nutrition 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
YNSYZWQSIHKJTA-UHFFFAOYSA-N 2-ethyl-3,4-dihydro-1h-isoquinolin-7-amine;hydrochloride Chemical compound Cl.C1=C(N)C=C2CN(CC)CCC2=C1 YNSYZWQSIHKJTA-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
206010065040 AIDS dementia complex Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
208000006264 Korsakoff syndrome Diseases 0.000 description 1
MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000036831 Moderate mental retardation Diseases 0.000 description 1
101100080274 Mus musculus Nos3 gene Proteins 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010050081 Neonatal hypoxia Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
206010036631 Presenile dementia Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
208000001407 Vascular Headaches Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
150000003997 cyclic ketones Chemical class 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
PIDPVVACBPWXLJ-UHFFFAOYSA-N methyl thiophene-2-carboximidothioate;hydroiodide Chemical compound I.CSC(=N)C1=CC=CS1 PIDPVVACBPWXLJ-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
YUVUODSQPBILGI-UHFFFAOYSA-N n'-(2-ethyl-3,4-dihydro-1h-isoquinolin-7-yl)thiophene-2-carboximidamide;hydrochloride Chemical compound Cl.C1=C2CN(CC)CCC2=CC=C1N=C(N)C1=CC=CS1 YUVUODSQPBILGI-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
229960004617 sapropterin Drugs 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
AFPMDKHZYQALNQ-UHFFFAOYSA-N thiophene-3-carbothioamide Chemical compound NC(=S)C=1C=CSC=1 AFPMDKHZYQALNQ-UHFFFAOYSA-N 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK1406-99A 1997-05-05 1998-04-28 Amidine derivatives, preparation method thereof, compositions containing them and their use for the treatment SK140699A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9701682A SE9701682D0 (sv)	1997-05-05	1997-05-05	Compounds
PCT/SE1998/000792 WO1998050380A1 (en)	1997-05-05	1998-04-28	Compounds

Publications (1)

Publication Number	Publication Date
SK140699A3 true SK140699A3 (en)	2000-06-12

Family

ID=20406836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1406-99A SK140699A3 (en)	1997-05-05	1998-04-28	Amidine derivatives, preparation method thereof, compositions containing them and their use for the treatment

Country Status (28)

Country	Link
US (1)	US6166030A (de)
EP (1)	EP0983266B1 (de)
JP (1)	JP2001523263A (de)
KR (1)	KR20010012227A (de)
CN (1)	CN1255130A (de)
AR (1)	AR012602A1 (de)
AT (1)	ATE210661T1 (de)
AU (1)	AU734394B2 (de)
BR (1)	BR9808725A (de)
CA (1)	CA2287999A1 (de)
DE (1)	DE69802923T2 (de)
DK (1)	DK0983266T3 (de)
EE (1)	EE9900475A (de)
ES (1)	ES2168757T3 (de)
HU (1)	HUP0003766A3 (de)
ID (1)	ID23156A (de)
IL (1)	IL132677A0 (de)
IS (1)	IS5237A (de)
MX (1)	MXPA99009874A (de)
NO (1)	NO995404L (de)
NZ (1)	NZ500676A (de)
PL (1)	PL336854A1 (de)
PT (1)	PT983266E (de)
SE (1)	SE9701682D0 (de)
SK (1)	SK140699A3 (de)
TR (1)	TR199902719T2 (de)
WO (1)	WO1998050380A1 (de)
ZA (1)	ZA983740B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1330901A (en) *	1999-10-06	2001-05-10	Brigham And Women's Hospital	Compounds and methods for modulating non-transcriptional effects of steroid hormones
US6683108B1 (en) *	2000-03-30	2004-01-27	Curis, Inc.	Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) *	2000-03-30	2006-10-03	Curis, Inc.	Small organic molecule regulators of cell proliferation
US8852937B2 (en) *	2000-03-30	2014-10-07	Curis, Inc.	Small organic molecule regulators of cell proliferation
US20030045449A1 (en) *	2001-08-15	2003-03-06	Pfizer, Inc.	Pharmaceutical combinations for the treatment of neurodegenerative diseases
BR0308524A (pt) *	2002-03-22	2005-02-01	Lg Life Sciences Ltd	Composto, e, processos para preparar o composto e a forma cristalina do composto
JP5833804B2 (ja)	2005-04-13	2015-12-16	ニューラクソン，インコーポレーテッド	Ｎｏｓ阻害活性を有する置換インドール化合物
TWI417099B (zh) *	2007-03-23	2013-12-01	Neuraxon Inc	具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
KR20100103799A (ko)	2007-11-16	2010-09-28	네우렉슨 인코포레이티드	내장통을 치료하기 위한 인돌 화합물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09504278A (ja) *	1944-06-01	1997-04-28	ザ、ウェルカム、ファンデーション、リミテッド	Ｎｏシンターゼインヒビターとしての置換尿素およびイソチオ尿素誘導体
US5807885A (en) *	1993-08-12	1998-09-15	Astra Aktiebolag	Amidine derivatives with nitric oxide synthetase activities
KR100342275B1 (ko) *	1993-10-21	2002-12-05	지.디. 썰 엘엘씨	산화질소신타제저해제로서유용한아미디노유도체
WO1996001817A1 (en) *	1994-05-07	1996-01-25	Astra Aktiebolag	Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
CZ287969B6 (cs) *	1995-08-10	2001-03-14	Astra Pharmaceuticals Limited	Amidinový derivát, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a použití

1997
- 1997-05-05 SE SE9701682A patent/SE9701682D0/xx unknown
- 1997-05-05 US US09/068,944 patent/US6166030A/en not_active Expired - Fee Related
1998
- 1998-04-24 AR ARP980101929A patent/AR012602A1/es not_active Application Discontinuation
- 1998-04-28 TR TR1999/02719T patent/TR199902719T2/xx unknown
- 1998-04-28 SK SK1406-99A patent/SK140699A3/sk unknown
- 1998-04-28 ID IDW991285A patent/ID23156A/id unknown
- 1998-04-28 IL IL13267798A patent/IL132677A0/xx unknown
- 1998-04-28 ES ES98921953T patent/ES2168757T3/es not_active Expired - Lifetime
- 1998-04-28 CA CA002287999A patent/CA2287999A1/en not_active Abandoned
- 1998-04-28 KR KR1019997010176A patent/KR20010012227A/ko not_active Withdrawn
- 1998-04-28 EP EP98921953A patent/EP0983266B1/de not_active Expired - Lifetime
- 1998-04-28 NZ NZ500676A patent/NZ500676A/en unknown
- 1998-04-28 WO PCT/SE1998/000792 patent/WO1998050380A1/en not_active Ceased
- 1998-04-28 AU AU74600/98A patent/AU734394B2/en not_active Ceased
- 1998-04-28 MX MXPA99009874A patent/MXPA99009874A/es unknown
- 1998-04-28 CN CN98804839A patent/CN1255130A/zh active Pending
- 1998-04-28 BR BR9808725-8A patent/BR9808725A/pt not_active IP Right Cessation
- 1998-04-28 HU HU0003766A patent/HUP0003766A3/hu unknown
- 1998-04-28 EE EEP199900475A patent/EE9900475A/xx unknown
- 1998-04-28 PT PT98921953T patent/PT983266E/pt unknown
- 1998-04-28 PL PL98336854A patent/PL336854A1/xx unknown
- 1998-04-28 DE DE69802923T patent/DE69802923T2/de not_active Expired - Fee Related
- 1998-04-28 DK DK98921953T patent/DK0983266T3/da active
- 1998-04-28 AT AT98921953T patent/ATE210661T1/de not_active IP Right Cessation
- 1998-04-28 JP JP54796898A patent/JP2001523263A/ja active Pending
- 1998-05-04 ZA ZA983740A patent/ZA983740B/xx unknown
1999
- 1999-11-01 IS IS5237A patent/IS5237A/is unknown
- 1999-11-04 NO NO995404A patent/NO995404L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU7460098A (en)	1998-11-27
PL336854A1 (en)	2000-07-17
IS5237A (is)	1999-11-01
NO995404D0 (no)	1999-11-04
KR20010012227A (ko)	2001-02-15
MXPA99009874A (es)	2004-09-30
AU734394B2 (en)	2001-06-14
WO1998050380A1 (en)	1998-11-12
IL132677A0 (en)	2001-03-19
HUP0003766A2 (en)	2001-03-28
PT983266E (pt)	2002-05-31
AR012602A1 (es)	2000-11-08
DE69802923T2 (de)	2002-07-04
EP0983266A1 (de)	2000-03-08
ES2168757T3 (es)	2002-06-16
DK0983266T3 (da)	2002-03-11
CN1255130A (zh)	2000-05-31
NO995404L (no)	2000-01-05
SE9701682D0 (sv)	1997-05-05
HUP0003766A3 (en)	2001-09-28
BR9808725A (pt)	2000-07-11
NZ500676A (en)	2001-05-25
TR199902719T2 (xx)	2000-02-21
EP0983266B1 (de)	2001-12-12
CA2287999A1 (en)	1998-11-12
ATE210661T1 (de)	2001-12-15
EE9900475A (et)	2000-06-15
US6166030A (en)	2000-12-26
ZA983740B (en)	1999-02-19
DE69802923D1 (de)	2002-01-24
JP2001523263A (ja)	2001-11-20
ID23156A (id)	2000-03-23

Publication	Publication Date	Title
JPH09501918A (ja)	1997-02-25	酸化窒素合成酵素活性を有するアミジン誘導体
US5972927A (en)	1999-10-26	Diazepinoindoles as phosphodiesterase 4 inhibitors
AU2018207402B2 (en)	2023-09-28	Bicyclic inhibitors of histone deacetylase
EP0782567B1 (de)	1999-06-30	Isothioharnstoff-derivate als no synthase hemmer
RU2157802C2 (ru)	2000-10-20	Бициклические производные изотиомочевины, способ их получения и фармацевтическая композиция на их основе
JPH10500138A (ja)	1998-01-06	酸化窒素合成酵素阻害剤としての２環アミジン誘導体
AU734394B2 (en)	2001-06-14	Compounds
EP0861250B1 (de)	2002-02-13	Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
US6489322B1 (en)	2002-12-03	Amidine derivatives as inhibitors of nitric oxide synthase
JP6880325B2 (ja)	2021-06-02	新規なｎ−［（ピリミジニルアミノ）プロパニル］−、ｎ−［（ピリジルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド
SK281442B6 (sk)	2001-03-12	Bicyklické amidínové deriváty, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
US5929085A (en)	1999-07-27	Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase
CZ388999A3 (cs)	2000-04-12	Sloučeniny
MXPA00001586A (es)	2004-09-27	Proceso para la creacion de un plano optico que genera una vision en tercera dimension.
CZ388899A3 (cs)	2000-04-12	Amidinové deriváty jako inhibitory syntasy oxidu dusnatého
US6140322A (en)	2000-10-31	Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
HUT77376A (hu)	1998-04-28	Biciklusos amidinszármazékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk